Your browser doesn't support javascript.
loading
Perspectives on the Designation of Oligonucleotide Starting Materials.
Kiesman, William F; McPherson, Andrew K; Diorazio, Louis J; Van den Bergh, Leo; Smith, Peter D; Northall, John M; Fettes, Alec; Wang, Tiejun; Mehlmann, Martin; Raza, Syed; Held, Gary.
Afiliação
  • Kiesman WF; Antisense Oligonucleotide Development and Manufacturing, Biogen, Inc., Cambridge, Massachusetts, USA.
  • McPherson AK; Process Organic Chemistry, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
  • Diorazio LJ; Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom.
  • Van den Bergh L; API Small Molecule Development, Janssen, Beerse, Belgium.
  • Smith PD; Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, United Kingdom.
  • Northall JM; Chemical Development, Product Development and Supply, GlaxoSmithKline, Stevenage, United Kingdom.
  • Fettes A; Pharmaceutical Division, Small Molecule Technical Development, Department of Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Wang T; Global Regulatory Affairs, CMC & Devices, Sanofi, Bridgewater, New Jersey, USA.
  • Mehlmann M; External Technical Oversight Analytics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Raza S; Amidite Manufacturing and Process Development, Thermo Fisher Scientific, Milwaukee, Wisconsin, USA.
  • Held G; Amidite Quality Control and Analytical Development, Thermo Fisher Scientific, Milwaukee, Wisconsin, USA.
Nucleic Acid Ther ; 31(2): 93-113, 2021 04.
Article em En | MEDLINE | ID: mdl-33534646
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligonucleotídeos Antissenso / RNA Interferente Pequeno / Indústria Farmacêutica / Doenças Genéticas Inatas Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligonucleotídeos Antissenso / RNA Interferente Pequeno / Indústria Farmacêutica / Doenças Genéticas Inatas Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article